🧪
hypothesis

TREM2-Mediated Selective Aggregate Clearance Pathway

Hypothesis

TREM2-Mediated Selective Aggregate Clearance Pathway

TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms.
🧬 TREM2🩺 neurodegeneration🎯 Composite 58%💱 $0.53▼30.6%proposed
🟡 ALS / Motor Neuron Disease🔴 Alzheimer's Disease🔮 Lysosomal / Autophagy🔥 Neuroinflammation
EvidencePending (0%)📖 25 cit🗣 3 debates 4 support 5 oppose
✓ All Quality Gates Passed
Mechanistic 0.60 (15%) Evidence 0.50 (15%) Novelty 0.85 (12%) Feasibility 0.55 (12%) Impact 0.70 (12%) Druggability 0.65 (10%) Safety 0.50 (8%) Competition 0.40 (6%) Data Avail. 0.60 (5%) Reproducible 0.45 (5%) KG Connect 0.91 (8%) 0.584 composite
🏆 ChallengeTREM2 Agonism vs Antagonism in Disease-Associated Microglia$2.5M →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite58%

🧪 Overview

TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Pathological Protein Aggregates"] --> B["Cross-Seeded Heterocomplexes"]
    A --> C["Homologous Aggregates"]

    B --> D["Uniquely Toxic Conformations"]
    D --> E["Enhanced Neuronal Damage"]

    F["TREM2 on Microglia"] --> G["Lipid Ligand Recognition"]
    G --> H["TREM2-DAP12 Signaling"]
    H --> I["SYK Kinase Activation"]

    I --> J["PI3K/AKT Pathway"]
    I --> K["PLCgamma Calcium Flux"]

    J --> L["Phagocytic Cup Formation"]
    K --> L

    L --> M["Selective Aggregate Recognition"]
    M --> N["Cross-Seeded Aggregate Uptake"]
    M --> O["Homologous Aggregate Sparing"]

    N --> P["Lysosomal Degradation"]
    P --> Q["Clearance of Toxic Species"]

    R["TREM2 Agonist Therapy"] --> S["Enhanced TREM2 Surface Expression"]
    S --> T["Boosted Phagocytic Capacity"]
    T --> M

    Q --> U["Reduced Cross-Seeding Cascade"]
    U --> V["Slowed Neurodegeneration"]

    style A fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
    style F fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
    style N fill:#1a3a2a,stroke:#81c784,color:#e0e0e0
    style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0

⚖️ Evidence

⚖️ Evidence Matrix3 supports3 contradicts
Supports
TREM2 variants significantly modify risk across multiple neurodegenerative diseases
PMID:31398344
Supports
Engineered TREM2 constructs can be designed to recognize specific protein conformations
PMID:29899446
Supports
TREM2 activation promotes microglial phagocytosis of protein aggregates
PMID:32719508
Contradicts
TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation
PMID:32719357
Contradicts
TREM2 activation may promote rather than clear certain protein aggregates in some contexts
PMID:33568819
Contradicts
Engineered immune receptors often lose specificity and cause off-target effects
PMID:31171062
📖 Linked Papers (24)Export BibTeX ↗
TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, leading to anxiety-like behaviors.
J Alzheimers Dis (2026) · PubMed:41930604 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Triggering Receptor Expressed on Myeloid Cells-2 Regulates Innate Lymphoid Cell Levels in Bleomycin-Induced Pulmonary Fibrosis.
Kaohsiung J Med Sci (2026) · PubMed:41928407 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Increased plasma soluble TREM2 levels in non-Alzheimer's dementia.
Acta neurologica Belgica (2026) · PubMed:41920402 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
TREM2 in neurodegeneration and diseases.
Molecular psychiatry (2026) · PubMed:41792456 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Plant-derived bioactive compounds modulate the gut microbiota in Alzheimer's disease: Metabolite signaling, neuroimmune circuits, and systems-level regulation.
Phytomedicine (2026) · PubMed:41678917 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, and therapeutic implications.
Ageing Res Rev (2026) · PubMed:41651180 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Loss of Triggering Receptor Expressed on Myeloid Cells 2 Impairs Microglial Function and Exacerbates Retinal Neurodegeneration in Glaucoma.
Am J Pathol (2026) · PubMed:41643896 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
AI-guided design of cyclic peptide binders targeting TREM2 using CycleRFdiffusion and experimental validation.
Bioorg Med Chem Lett (2026) · PubMed:41435973 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Microglia, Trem2, and Neurodegeneration.
Neuroscientist (2025) · PubMed:38769824 ↗
5 figures
Figure 1.
Figure 1.
Historical milestones in microglia-Trem2 research. Schematic illustration of the key milestone events from various research groups that contributed to the disco...
Figure 2.
Figure 2.
Domain structure of the Trem2 protein and its association with Alzheimer disease (AD) risk. ( A ) Human Trem2 protein domain structure: this schematic illustrat...
Microglia, Trem2, and Neurodegeneration.
The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry (2025) · PubMed:38769824 ↗
5 figures
Figure 1.
Figure 1.
Historical milestones in microglia-Trem2 research. Schematic illustration of the key milestone events from various research groups that contributed to the disco...
Figure 2.
Figure 2.
Domain structure of the Trem2 protein and its association with Alzheimer disease (AD) risk. ( A ) Human Trem2 protein domain structure: this schematic illustrat...
TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration.
Immunity (2023) · PubMed:37442133 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.
Neuron (2023) · PubMed:36368315 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
📙 Related Wiki Pages (15)
PSP Therapeutic IdeastreatmentAlzheimer's Drug Discovery Foundation (AinstitutionCorticobasal Syndrome (CBS) TreatmenttherapeuticsPRX005entityEEDgeneTREM2 ProteinproteinTREM2 — Triggering Receptor Expressed ongeneTREM2 Modulator TherapytherapeuticTREM2-Targeting Therapiestherapeutictrem2-alpha-synuclein-clearance-parkinsogeneralNeurodegenerationdiseaseAlibaba Tongyi Qianwen-Bio (Chinese Biomai_toolTREM2 Mechanism HubmechanismTREM2 Protein (Triggering Receptor Expreentitytrem2-therapeuticstherapeutic

🏥 Translation

🧬 3D Protein Structure — TREM2

🧬 PDB 6YXY Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TREM2 from GTEx v10.

Spinal cord cervical c-148.4 Substantia nigra20.7 Hypothalamus10.9 Hippocampus9.8 Amygdala8.9 Caudate basal ganglia7.9 Putamen basal ganglia6.6 Nucleus accumbens basal ganglia6.2 Anterior cingulate cortex BA245.6 Frontal Cortex BA95.1 Cortex3.5 Cerebellar Hemisphere2.9 Cerebellum1.5median TPM (GTEx v10)

💉 Clinical Trials (5)Relevance: 26%

0
Active
0
Completed
1,820
Total Enrolled
NA
Highest Phase
The Signature of Alzheimer's Disease in Subjective Cognitive DeclineUnknown
RECRUITING·NCT07402161 · IRCCS Policlinico S. Donato
250 enrolled · 2025-10-01 · → 2027-10-01
This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging
Subjective Cognitive Decline (SCD) Subjective Cognitive Complaints (SCCs) Subjective Cognitive Impairment
Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's DiseaseUnknown
COMPLETED·NCT06224920 · Ludwig-Maximilians - University of Munich
140 enrolled · 2017-01-01 · → 2024-01-01
The temporal sequence of microglial activation, changes in functional and structural connectivity and the progression of neurocognitive deficits has not been conclusively clarified. To date, there hav
Alzheimer Disease Corticobasal Syndrome
magnetic resonance imaging electroencephalography blood and CSF biomarker
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia DiagnosisUnknown
RECRUITING·NCT06339190 · Monash University
1,000 enrolled · 2021-08-01 · → 2025-12
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level
Neurodegenerative Diseases Dementia
Venepuncture
Physical Activity in Patients With Parkinson's Disease: a "Disease Modifying" Intervention?NA
TERMINATED·NCT05815524 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
30 enrolled · 2022-05-02 · → 2024-12-31
Parkinson's disease (PD) is a neurodegenerative disease characterized by bradykinesia, rigors, and tremor at rest. Distinctive neuropathological signs include progressive loss of dopaminergic neurons
Parkinson Disease
Physical activity training
Clinical, Molecular and Electrophysiological Profiling of Parkinson's Disease: the Role of Non-pharmacological TherapiesNA
UNKNOWN·NCT05807581 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
400 enrolled · 2023-06-09 · → 2025-05-30
In Parkinson's disease (PD), direct evidence linking inflammation to the harmful activities of alpha-synuclein (a-syn) aggregates, the disease onset, and its progression is still lacking. This transla
Parkinson Disease
physical activity iTBS

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TREM2 →

No DepMap CRISPR Chronos data found for TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline
2.0 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 1.4%
Volatility
Medium
0.0402
Events (7d)
6
Price History
▼30.6%

💾 Resource Usage

LLM Tokens
36,356
$0.2181
Total Cost
$0.2181

🔮 Predictions

🔎 Predictions vs Observations4 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
If hypothesis is true, intervention serve as specific molecular targets for engineered clearance systemsserve as specific molecular targets for engineered clearance systems— no observation —pending0.50
If hypothesis is true, intervention focus on structural characterization of cross-seeded aggregates using cryo-electron microscopy and hydrogen-deuterium exchange mass spectrometry to identify unique focus on structural characterization of cross-seeded aggregates using cryo-electron microscopy and hydrogen-deuterium exchange mass spectrometry to identify uni— no observation —pending0.50
If hypothesis is true, intervention require a systematic experimental approach combining protein engineering, cell biology, and in vivo testingrequire a systematic experimental approach combining protein engineering, cell biology, and in vivo testing— no observation —pending0.50
If hypothesis is true, intervention revolutionize treatment approaches for neurodegenerative diseasesrevolutionize treatment approaches for neurodegenerative diseases— no observation —pending0.50
🔮 Falsifiable Predictions (4)
pendingconf 50%
If hypothesis is true, intervention require a systematic experimental approach combining protein engineering, cell biology, and in vivo testing
Predicted outcome: require a systematic experimental approach combining protein engineering, cell biology, and in vivo testing
Falsification: Intervention fails to require a systematic experimental approach combining protein engineering, cell biology, and in vivo testing
pendingconf 50%
If hypothesis is true, intervention focus on structural characterization of cross-seeded aggregates using cryo-electron microscopy and hydrogen-deuterium exchange mass spectrometry to identify unique conformational epitopes
Predicted outcome: focus on structural characterization of cross-seeded aggregates using cryo-electron microscopy and hydrogen-deuterium exchange mass spectrometry to id
Falsification: Intervention fails to focus on structural characterization of cross-seeded aggregates using cryo-electron microscopy and hydrogen-deuterium exchange mass spectrometry to identify unique conformational
pendingconf 50%
If hypothesis is true, intervention serve as specific molecular targets for engineered clearance systems
Predicted outcome: serve as specific molecular targets for engineered clearance systems
Falsification: Intervention fails to serve as specific molecular targets for engineered clearance systems
pendingconf 50%
If hypothesis is true, intervention revolutionize treatment approaches for neurodegenerative diseases
Predicted outcome: revolutionize treatment approaches for neurodegenerative diseases
Falsification: Intervention fails to revolutionize treatment approaches for neurodegenerative diseases
View on SciDEX ↗